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Abstract
The epidemiology of hospital-acquired bloodstream infections (HABSIs) based on the Belgian national surveillance program was analyzed
(2000–2014). Our mixed-effects regression analysis identified increased rates of Escherichia coli, Klebsiella pneumoniae, and Enterococcus
faecium. HABSI incidence and resistance patterns should be further monitored because of their impact on proper empiric antibiotic therapy.
(Received 20 November 2018; accepted 15 February 2019)
Hospital-acquired bloodstream infections (HABSIs) are an impor-
tant cause of increased morbidity, mortality, length of stay, and
costs.1–3 Although surveillance of blood cultures may not fully re-
present the epidemiology of all underlying infections, namely those
without bacteremia, the clinical relevance of these invasive isolates
is indisputable.4 The Belgian institution Sciensano, previously
WIV-ISP, has headed the national “Surveillance of Bloodstream
Infections in Hospitals” program. This surveillance program has
encouraged hospitals to participate and to collect hospital-wide
HABSI case-based data since 1992. Identifying incidence rates,
origins, microorganisms, and their trends is essential to character-
izing the burden of hospital-acquired infections. In this study, we
aimed to analyze HABSI incidence trends (2000–2014) with sub-
group analyses for microorganism, origin of infection, and accord-
ing to setting (ie, intensive care unit (ICU) or university hospital).
Methods
Study design and setting
A national dynamic cohort study of HABSI epidemiology was
performed based on the Belgian “Surveillance Data of BSI in
Hospitals” program from January 2000 to December 2014.5
Participants
Participation requires case-based recording of all HABSI for a
minimum of 3 consecutive months annually. Participation became
mandatory from 2014 onward; eligible hospitals were all acute- and
chronic-care hospitals with >150 beds. Hospitals included in this
cohort study reported both HABSI (numerator) and patient day
(denominator) data for at least 1 trimester during at least 5 years.
Case definitions and variables
HABSI is defined as BSI with onset 2 or more days after hospital
admission, not present upon admission (Appendix 1 online). A
BSI requires at least 2 separate cultures with clinical symptoms if
the causal microorganism is a skin commensal or with 1 culture of
a recognized pathogen. HABSI origins are classified as central-line
associated, secondary, or unknown.6 CLABSI was defined as BSI
with concomitant catheter culture or a central venous catheter
(CVC) in place within 2 days of BSI onset, unrelated to another
infectious site. CDC CLABSI surveillance definitions were applied
post hoc to HABSI of unknown origin with a CVC in place in the
previous 48 hours.7 Collected data include HABSI onset date, prob-
able infectious origin, causal microorganism(s), setting (hospital
ward or ICU), and hospital type [(university-affiliated or acute-
care versus chronic-care [ie, >14-day average length of stay]).
Denominator data included number of hospital-wide and ICU
patient days per trimester. HABSI incidence was reported as a
mean rate per 10,000 patient days hospital-wide and mean rate
per 1000 ICU patient days. Antibiotic resistance data collection was
mandatory from 2013 to 2014 for Staphylococcus aureus (oxacillin,
vancomycin), Enterococcus spp (vancomycin), Enterobacteriaceae
(third-generation cephalosporin, carbapenem), Pseudomonas aeru-
ginosa (carbapenem), and Acinetobacter spp (carbapenem).
Statistical methods
Mixed-effects negative binomial regression analysis was used
to calculated adjusted incidence rate ratios (IRRs) with 95% con-
fidence interval (CI) to determine the annual change in total
HABSI rate (Appendix 2 online). Fixed confounding factors were
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university hospital status, chronic care facility, and risk exposure
(patient days per trimester). Mixed effects were applied to adjust
for varying hospital participation and characteristics. This analysis
was applied for total, gram-negative, and gram-positive HABSI
rates. Subgroup analyses were performed for ICUs, university
hospitals, and the most common microorganisms. In the regres-
sion analysis, we calculated both relative (incidence rate ratio)
and absolute infection rate changes (per 10,000 patient days).
Antibiotic resistance data were classified as sensitive or resistant
(intermediate or complete resistance).
In our sensitivity analysis, we evaluated selection bias by repeat-
ing the analyses of HABSI rates with 3 different hospital cohorts
with varying levels of participation: ≥1 trimester for ≥3 years,
≥1 trimester for ≥10 years, or 4 trimesters for ≥3 years.
Statistical analyses were performed using Stata version 14 soft-
ware (StataCorp, College Station, TX). P ≤ .05 was considered
statistically significant.
Results
In total, 110 hospitals participated for at least 1 trimester for
5 years. This cohort included 56 450 patients with 59,941 HABSIs
from 66,610 microorganisms. Table 1 presents the included
hospital characteristics. Missing quarterly patient day data led to
the exclusion of 91 HABSI hospital-wide (0.2%) and 1,265 from
the ICU (9.8%). We detected a 6-fold higher infection rate in
ICUs (4.4 HABSIs per 1,000 patient days; IQR, 2.8–7.2) versus
hospital-wide (6.8 HABSIs per 1,000 patient days; IQR, 4.6–9.4).
The CLABSI rates were 1.6 HABSIs per 1,000 patient days (IQR
0.9–2.8) hospital-wide and 1.8 HABSIs per 1,000 patient days
(IQR, 0.9–2.7) in the ICUs.
HABSIs were primarily central-line associated (24.2%) or were
of urinary tract (14.9%) or pulmonary origin (9.7%). An important
proportion of HABSIs (27.8%) were of unknown origin. The most
common microorganisms were coagulase-negative staphylococci
(CNS, 18.6%), E. coli (18.0%), and S. aureus (11.6%), followed
by Enterococcus (7.8%), Klebsiella (7.1%), Enterobacter (6.1%),
Candida (5.7%), and Pseudomonas spp (5.6%). Approximately
10% of HABSIs were polymicrobial (9.7%).
Our mixed-effects regression analysis identified a decrease in
total HABSI rates (IRR, −0.5%; 95% CI, −0.8 to −0.1; P= .006).
However, this effect size was small and the incidence trend dem-
onstrated cyclical, fluctuating rates (Appendix 3 online). This trend
was nonsignificant within the subgroup of university hospitals
(IRR, −0.6%; 95% CI, −1.3 to −0.1; P= .08). CLABSI rates did
not decrease either hospital-wide (IRR,þ0.1%; 95%CI,−0.6 to 0.8;
P= .73) or in intensive care (IRR, −0.6%; −1.7 to 0.6; P= .32). The
rate of HABSIs of unknown origin decreased over the year (IRR,
−5.8%; 95% CI,−6.6 to−5.1; P< .001) with concomitant increases
in HABSIs of all secondary origins.
Compared with other hospitals, university hospitals demon-
strated higher infection rates for hospital-wide total HABSIs (IRR,
2.3; 95%CI, 1.7–3.2; P< .001), CLABSIs (IRR, 3.4; 95%CI, 2.0–5.9;
P < .001), and total ICU HABSIs (IRR, 1.4; 95% CI, 1.0–1.96;
P= .04). ICU CLABSIs were not significantly higher among uni-
versity hospitals (IRR, 1.6; 95% CI, 0.95–2.6; P= .08).
Although the total rate exhibited minimal change, HABSI rates
changed significantly in opposite directions for gram-positive
and gram-negative bacteria. Gram-negative infections increased
(IRR, þ1.0%; 95% CI, 0.6–1.4; P < .001), whereas gram-positive
HABSIs decreased (IRR, −1.8; 95% CI, −2.2 to −1.3; P < .001)
(Appendix 4 online). This finding corresponds with an increase
in the gram-negative proportion from 42.7% to 54.1%. The largest
incidence rate changes were increases in E. coli (IRR, þ2.8%; 95%
CI, 2.2–3.3; P < .001) and decreases in CNS (IRR, −4.5%; 95%
CI, −5.2 to −3.8; P < .001) (Fig. 1A). Although the absolute
increase was less prominent, Klebsiella pneumoniae (IRR, þ4.4%;
95%CI, 3.4–5.4; P< .001) and Enterococcus faecium (IRR,þ10.9%;
95% CI, 9.0–12.8; P < .001) demonstrated relative rate increases
that were large compared to their baseline rate. Notably, E. faecium
displayed a nearly 10-fold increase among university hospitals
(0.11–0.96 per 10,000 patient days). The low rates of Enterobacter
aerogenes decreased further over the study period (IRR, −6.1%;
95% CI, −7.4 to −4.7; P < .001). Although statistically significant,
Table 1. Hospital Characteristics and Hospital-Acquired Bloodstream Infection Incidence
Variable
Surveillance Year, No.
2000–2002 2003–2005 2006–2008 2009–2011 2012–2014 Total
Hospital-wide
Hospitals 82 90 101 87 94 110
Total HABSI 10,371 12,283 13,997 10,682 12,608 59,941
CLABSI 2,293 3,004 3,410 2,540 3,265 14,512
Patient-days 12,626,277 14,325,252 16,118,362 13,539,573 15,804,997 72,414,464
Intensive care
ICUs 78 81 87 77 87 105
Total HABSI 2,067 2,715 2,581 1,821 2,441 11,625
CLABSI 589 772 775 595 827 3,578
Patient-days 390,207 502,807 552,109 401,660 548,153 2,394,936
Hospital type
University 4 6 6 6 6 6
Chronic care 0 1 4 4 4 5
Note. HABSI, hospital-acquired bloodstream infection; CLABSI, central line-associated bloodstream infection.
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the incidence rates of S. aureus (IRR, −0.8%; 95% CI, −1.5 to −0.2;
P= .02) and Candida spp (IRR, −1.3%; 95% CI, −2.2 to −0.4;
P= .004) did not exhibit a large absolute decrease. Hospital-wide
trends of Klebsiella oxytoca, Enterobacter cloacae, P. aeruginosa,
Bacteroides spp and Candida glabrata remained stable.
Among ICUs, the CNS rate demonstrated a similar decrease,
whereas gram-negative and Candida rates remained stable.
However, E. coli, K. pneumoniae, E. cloacae, and E. faecium
increased, whereas P. aeruginosa and Enterobacter aerogenes
decreased (Fig. 1B).
Methicillin-resistant S. aureus accounted for 19.0% of isolates.
Vancomycin-resistant Enterococcus was uncommon (2.7%).
Third-generation cephalosporin resistance was common among
E. coli (16.2%), Klebsiella spp (24.8%), Enterobacter spp (48.2%)
and P. aeruginosa (14.6%). Carbapenem resistance was present
among P. aeruginosa (18.2%) and Acinetobacter (8.1%) but was
uncommon among Enterobacteriaceae (<2.5%).
Among total HABSI incidence, goodness of fit identified
2 severe regression model outliers. However, removal thereof
did not meaningfully affect the results (Appendix 5 online).
Sensitivity analysis was performed to assess selection bias associ-
ated with varying participation criteria (Appendix 6 online). The
hospital-wide rise in gram-negative and decline in gram-positive
and fungal rates remained significant among all cohorts, albeit with
slightly different effect sizes. Hospitals participating ≥10 years
showed attenuation of the increasing gram-negative rate, stronger
rate reductions among gram-positive HABSI, and a nonsignificant
trend toward lower CLABSI rates (IRR, −0.7%; 95% CI, −1.4
to 0.1; P= .07).
Discussion
In this study, we analyzed HABSI trends over 15 years of surveil-
lance (2000–2014) in 110 hospitals. Although the total HABSI rate
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Fig. 1. A. Hospital-wide hospital-acquired bloodstream infection incidence, per microorganism (2000–2014). Incidence of hospital-wide bloodstream infections for
microorganisms that demonstrated significant annual incidence rate ratio changes over the years (see online appendix 4). Note. CNS, coagulase-negative staphylococci.
B. Intensive care hospital-acquired bloodstream infection incidence, per microorganism (2000–2014). Incidence of intensive care bloodstream infections for microorganisms
that demonstrated significant annual incidence rate ratio changes over the years (see online appendix 4). Note. CNS, coagulase-negative staphylococci.
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was slightly decreasing, there was a clear increase in gram-negative
pathogen incidence represented by E. coli and K. pneumoniae.
Enterococcus faecium demonstrated important rate increases,
most markedly within ICUs and university-affiliated hospitals.
Among ICUs the gram-negative HABSI rate remained stable
yet the proportions of specific microorganisms changed with
increases in E. coli, K. pneumoniae, and E. cloacae and decreases in
P. aeruginosa and E. aerogenes. Notably, within the ICU, the inci-
dence of E. faecium rose to the same level as K. pneumoniae and
E. cloacae.
CLABSI rates did not decrease either hospital-wide or in ICUs.
University hospitals displayed hospital-wide CLABSI rates triple
that of nonuniversity hospitals, yet this difference was not signifi-
cant among ICUs. This higher infection rate among university hos-
pital wards may reflect an area for improvement through CLABSI
prevention initiatives. The subgroup of hospitals participating at
least 10 years exhibited a nonsignificant trend toward decreasing
CLABSI rates, which aligns with evidence that CLABSI reduction
can be achieved through long-term surveillance as part of a quality
improvement initiative.8
The strengths of this study include the long-term surveillance,
hospital-wide data collection, nationwide participation, andmixed-
effects modeling to account for confounding factors. Countrywide
surveillance programs have been shown to estimate valid BSI
incidences when data are collected during random trimesters of the
year.9 In this study, hospitals could choosewhich trimester to report
from, but there was no statistically significant difference in report-
ing rates between trimesters. Furthermore, the hospital cohort
reporting data year-round exhibited similar rate changes compared
to cohorts that did not.
The limitations of this study include missing data on con-
founding factors such as catheter days, blood culturing frequency,
and recent ICU admission. No distinction could be made between
infections acquired in the ICU versus HABSIs that led to ICU
admission. Finally, because it was not mandatory to perform
surveillance consecutively across trimesters or years, time-series
regression analysis with temporal autocorrelation was not possible
without exclusion of most of the data, at the expense of its external
validity. Unfortunately, because resistance data were only available
during the final 2 surveillance years, resistance trends could not be
analyzed in this cohort.
Overall, CNSs comprised the majority of CLABSI and demon-
strated rate decreases both in intensive care and hospital-wide,
yet CLABSI incidence appeared to remain stable. Although the def-
inition requires at least 2 positive cultures with clinical symptoms,
this CNS decline could partially represent an improved recognition
of skin contaminants instead of a true incidence decline.
This study identified an increasing HABSI rate for E. coli,
K. pneumoniae, and E. faecium, which represents an increased
treatment burden and the underlying epidemiology of hospital-
acquired infections. This is alarming because of these micro-
organisms’ resistance levels to fluoroquinolones, third-generation
cephalosporins, and amoxicillin. Escherichia coli, K. pneumoniae,
E. cloacae, and E. faecium increases were mirrored in the ICU,
reflecting their clinical importance as either representing sepsis
requiring critical care admission or infection of susceptible ICU
patients.10–12 Other surveillance studies have likewise identified
rises in E. coli and K. pneumoniae13–16 and increasing proportions
of E. coli resistant to third-generation cephalosporins among 12
of 30 European countries.4 Increasing trends of antimicrobial-
resistant microorganisms threatens to complicate proper early
and appropriate antibiotic treatment.17 Empiric antibiotic therapy
should be based on local epidemiology, and these changing trends
warrant further monitoring of microorganism incidence and resis-
tance patterns.
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